Mechanisms involved in the anti-inflammatory properties of native and genetically engineered lactic acid bacteria

Anti-Infective Agents

Volumn 11, Issue 1, 2012, Pages 59-69

  LeBlanc, Jean Guy ^a   del Carmen, Silvina ^a   Turk, Meritxell Zurita ^b   Lima, Fernanda Alvarenga ^b   Pontes, Daniela Santos ^b   Miyoshi, Anderson ^b   Azevedo, Vasco ^b   de LeBlanc, Alejandra de Moreno ^a  

^a CENTRO DE REFERENCIA PARA LACTOBACILOS CERELA CONICET   (Argentina)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Anti inflammatory; Antioxidant; Catalase; Immune regulation; Interleukin 10; Lactic acid bacteria; Superoxide dismutase

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOTEICHOIC ACID; MESALAZINE; PEPTIDOGLYCAN; PLACEBO; PROBIOTIC AGENT; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANTIOXIDANT ACTIVITY; ARTICLE; BREAST CANCER; DRUG EFFICACY; ENTERITIS; FERMENTATION; GENETIC ENGINEERING; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; INFLAMMATION; INTESTINE FLORA; INTESTINE MUCOSA; LACTIC ACID BACTERIUM; NONHUMAN; OXIDATIVE STRESS; PHASE 1 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); UNSPECIFIED SIDE EFFECT;

EID: 84872238916     PISSN: 22113525     EISSN: 22113533     Source Type: Journal    
DOI: 10.2174/22113626130107     Document Type: Article

References (93)

1. Fuller, R. History and development of probiotics. In Probiotics-The Scientific Basis, R. Fuller, ed.; Chapman and Hall: New York, 1992, pp. 1-8.
2. Heyman, M.; Menard, S. Probiotic microorganisms: how they affect intestinal pathophysiology. Cell Mol. Life Sci. 2002, 59, 1151-1165.
3. Guarner, F.; Malagelada, J. R. Role of bacteria in experimental colitis. Best Pract Res Clin Gastroenterol. 2003, 17, 793-804.
4. Isolauri, E.; Salminen, S.; Ouwehand, A. C. Microbial-gut interactions in health and disease. Probiotics. Best Pract Res Clin Gastroenterol. 2004, 18, 299-313.
5. Perdigon, G.; Vintini, E.; Alvarez, S.; Medina, M.; Medici, M. Study of the possible mechanisms involved in the mucosal immune system activation by lactic acid bacteria. J. Dairy Sci., 1999, 82, 1108-1114.
6. de Moreno de LeBlanc, A.; Perdigon, G. Yogurt feeding inhibits promotion and progression of experimental colorectal cancer. Med Sci. Monit., 2004, 10, BR96-104.
7. Pessi, T.; Sutas, Y.; Hurme, M.; Isolauri, E. Interleukin-10 generation in atopic children following oral Lactobacillus rhamnosus GG. Clin. Exp. Allergy, 2000, 30, 1804-1808.
8. Rautava, S.; Kalliomaki, M.; Isolauri, E. Probiotics during pregnancy and breast-feeding might confer immunomodulatory protection against atopic disease in the infant. J. Allergy Clin. Immunol., 2002, 109, 119-121.
9. Perdigon, G.; Medina, M.; Vintini, E.; Valdez, J. C. Intestinal pathway of internalisation of lactic acid bacteria and gut mucosal immunostimulation. Int. J. Immunopathol. Pharmacol., 2000, 13, 141-150.
10. Pena, J. A.; Versalovic, J. Lactobacillus rhamnosus GG decreases TNF-alpha production in lipopolysaccharide-activated murine macrophages by a contact-independent mechanism. Cell Microbiol., 2003, 5, 277-285.
11. Maassen, C. B.; van Holten-Neelen, C.; Balk, F.; den Bak-Glashouwer, M. J.; Leer, R. J.; Laman, J. D.; Boersma, W. J.; Claassen, E. Straindependent induction of cytokine profiles in the gut by orally administered Lactobacillus strains. Vaccine, 2000, 18, 2613-2623.
12. Mileti, E.; Matteoli, G.; Iliev, I. D.; Rescigno, M. Comparison of the immunomodulatory properties of three probiotic strains of Lactobacilli using complex culture systems: prediction for in vivo efficacy. PLoS One, 2009, 4, e7056.
13. Zakostelska, Z.; Kverka, M.; Klimesova, K.; Rossmann, P.; Mrazek, J.; Kopecny, J.; Hornova, M.; Srutkova, D.; Hudcovic, T.; Ridl, J.; Tlaskalova-Hogenova, H. Lysate of Probiotic Lactobacillus casei DN-114 001 Ameliorates Colitis by Strengthening the Gut Barrier Function and Changing the Gut Microenvironment. PLoS One, 6, e27961.
14. Macho Fernandez, E.; Valenti, V.; Rockel, C.; Hermann, C.; Pot, B.; Boneca, I. G.; Grangette, C. Anti-inflammatory capacity of selected lactobacilli in experimental colitis is driven by NOD2-mediated recognition of a specific peptidoglycan-derived muropeptide. Gut, 60, 1050-1059.
15. Matsuguchi, T.; Takagi, A.; Matsuzaki, T.; Nagaoka, M.; Ishikawa, K.; Yokokura, T.; Yoshikai, Y. Lipoteichoic acids from Lactobacillus strains elicit strong tumor necrosis factor alpha-inducing activities in macrophages through Toll-like receptor 2. Clin Diagn Lab Immunol. 2003, 10, 259-266.
16. Claes, I. J.; Lebeer, S.; Shen, C.; Verhoeven, T. L.; Dilissen, E.; De Hertogh, G.; Bullens, D. M.; Ceuppens, J. L.; Van Assche, G.; Vermeire, S.; Rutgeerts, P.; Vanderleyden, J.; De Keersmaecker, S. C. Impact of lipoteichoic acid modification on the performance of the probiotic Lactobacillus rhamnosus GG in experimental colitis. Clin. Exp. Immunol., 2010, 162, 306-314.
17. Guslandi, M.; Mezzi, G.; Sorghi, M.; Testoni, P. A. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig. Dis. Sci., 2000, 45, 1462-1464.
18. Gupta, P.; Andrew, H.; Kirschner, B. S.; Guandalini, S. Is lactobacillus GG helpful in children with Crohn's disease? Results of a preliminary, open-label study. J. Pediatr. Gastroenterol. Nutr., 2000, 31, 453-457.
19. Malin, M.; Suomalainen, H.; Saxelin, M.; Isolauri, E. Promotion of IgA immune response in patients with Crohn's disease by oral bacteriotherapy with Lactobacillus GG. Ann. Nutr. Metab., 1996, 40, 137-145.
20. O'Mahony, L.; McCarthy, J.; Kelly, P.; Hurley, G.; Luo, F.; Chen, K.; O'Sullivan, G. C.; Kiely, B.; Collins, J. K.; Shanahan, F.; Quigley, E. M. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology, 2005, 128, 541-551.
21. Cui, H. H.; Chen, C. L.; Wang, J. D.; Yang, Y. J.; Cun, Y.; Wu, J. B.; Liu, Y. H.; Dan, H. L.; Jian, Y. T.; Chen, X. Q. Effects of probiotic on intestinal mucosa of patients with ulcerative colitis. World J. Gastroenterol., 2004, 10, 1521-1525.
22. Kajander, K.; Korpela, R. Clinical studies on alleviating the symptoms of irritable bowel syndrome. Asia Pac. J. Clin. Nutr., 2006, 15, 576-580.
23. Bittner, A. C.; Croffut, R. M.; Stranahan, M. C.; Yokelson, T. N. Prescript-assist probiotic-prebiotic treatment for irritable bowel syndrome: an open-label, partially controlled, 1-year extension of a previously published controlled clinical trial. Clin. Ther., 2007, 29, 1153-1160.
24. Bittner, A. C.; Croffut, R. M.; Stranahan, M. C. Prescript-Assist probiotic-prebiotic treatment for irritable bowel syndrome: a methodologically oriented, 2-week, randomized, placebo-controlled, double-blind clinical study. Clin. Ther., 2005, 27, 755-761.
25. Choi, C. H.; Jo, S. Y.; Park, H. J.; Chang, S. K.; Byeon, J. S.; Myung, S. J. A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life. J. Clin. Gastroenterol., 2011, 45, 679-683.
26. Mimura, T.; Rizzello, F.; Helwig, U.; Poggioli, G.; Schreiber, S.; Talbot, I. C.; Nicholls, R. J.; Gionchetti, P.; Campieri, M.; Kamm, M. A. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut, 2004, 53, 108-114.
27. Gionchetti, P.; Rizzello, F.; Helwig, U.; Venturi, A.; Lammers, K. M.; Brigidi, P.; Vitali, B.; Poggioli, G.; Miglioli, M.; Campieri, M. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology, 2003, 124, 1202-1209.
28. Pronio, A.; Montesani, C.; Butteroni, C.; Vecchione, S.; Mumolo, G.; Vestri, A.; Vitolo, D.; Boirivant, M. Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells. Inflamm. Bowel. Dis., 2008, 14, 662-668.
29. Furrie, E.; Macfarlane, S.; Kennedy, A.; Cummings, J. H.; Walsh, S. V.; O'Neil D, A.; Macfarlane, G. T. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut, 2005, 54, 242-249.
30. Kruis, W.; Fric, P.; Pokrotnieks, J.; Lukas, M.; Fixa, B.; Kascak, M.; Kamm, M. A.; Weismueller, J.; Beglinger, C.; Stolte, M.; Wolff, C.; Schulze, J. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut, 2004, 53, 1617-1623.
31. Tursi, A.; Brandimarte, G.; Giorgetti, G. M.; Forti, G.; Modeo, M. E.; Gigliobianco, A. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med. Sci. Monit., 2004, 10, PI126-131.
32. Venturi, A.; Gionchetti, P.; Rizzello, F.; Johansson, R.; Zucconi, E.; Brigidi, P.; Matteuzzi, D.; Campieri, M. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther., 1999, 13, 1103-1108.
33. Karimi, O.; Pena, A. S.; van Bodegraven, A. A. Probiotics (VSL#3) in arthralgia in patients with ulcerative colitis and Crohn's disease: a pilot study. Drugs Today (Barc), 2005, 41, 453-459.
34. Miele, E.; Pascarella, F.; Giannetti, E.; Quaglietta, L.; Baldassano, R. N.; Staiano, A. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am. J. Gastroenterol., 2009, 104, 437-443.
35. Hedin, C. R.; Mullard, M.; Sharratt, E.; Jansen, C.; Sanderson, J. D.; Shirlaw, P.; Howe, L. C.; Djemal, S.; Stagg, A. J.; Lindsay, J. O.; Whelan, K. Probiotic and prebiotic use in patients with inflammatory bowel disease: a case-control study. Inflamm. Bowel. Dis., 2010, 16, 2099-2108.
36. Rachmilewitz, D.; Katakura, K.; Karmeli, F.; Hayashi, T.; Reinus, C.; Rudensky, B.; Akira, S.; Takeda, K.; Lee, J.; Takabayashi, K.; Raz, E. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology, 2004, 126, 520-528.
37. Ulisse, S.; Gionchetti, P.; D'Alo, S.; Russo, F. P.; Pesce, I.; Ricci, G.; Rizzello, F.; Helwig, U.; Cifone, M. G.; Campieri, M.; De Simone, C. Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment. Am. J. Gastroenterol, 2001, 96, 2691-2699.
38. de Moreno de LeBlanc, A.; del Carmen, S.; Zurita-Turk, M.; Santos Rochat, C.; van de Guchte, M.; Azevedo, V.; Miyoshi, A.; Le-Blanc, J.G. Importance of IL-10 modulation by probiotic microorganisms in gastrointestinal inflammatory diseases. ISRN Gastroenterology, 2011, doi:10.5402/2011/892971.
39. Carol, M.; Borruel, N.; Antolin, M.; Llopis, M.; Casellas, F.; Guarner, F.; Malagelada, J. R. Modulation of apoptosis in intestinal lymphocytes by a probiotic bacteria in Crohn's disease. J. Leukoc Biol., 2006, 79, 917-922.
40. Kuhn, R.; Lohler, J.; Rennick, D.; Rajewsky, K.; Muller, W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell, 1993, 75, 263-274.
41. Tilg, H.; van Montfrans, C.; van den Ende, A.; Kaser, A.; van Deventer, S. J.; Schreiber, S.; Gregor, M.; Ludwiczek, O.; Rutgeerts, P.; Gasche, C.; Koningsberger, J. C.; Abreu, L.; Kuhn, I.; Cohard, M.; LeBeaut, A.; Grint, P.; Weiss, G. Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. Gut, 2002, 50, 191-195.
42. Agresti, P. M.; Gala-García, A.; LeBlanc, J. G.; de Moreno de LeBlanc, A.; Azevedo, V.; Miyoshi, A. Uso potencial de bacterias lácticas como vehículos vacúnales, Vacunas, 2012, 13, 15-20.
43. Steidler, L.; Hans, W.; Schotte, L.; Neirynck, S.; Obermeier, F.; Falk, W.; Fiers, W.; Remaut, E. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science, 2000, 289, 1352-1355.
44. Braat, H.; Rottiers, P.; Hommes, D. W.; Huyghebaert, N.; Remaut, E.; Remon, J. P.; van Deventer, S. J.; Neirynck, S.; Peppelenbosch, M. P.; Steidler, L. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin. Gastroenterol Hepatol., 2006, 4, 754-759.
45. Menard, S.; Candalh, C.; Bambou, J. C.; Terpend, K.; Cerf-Bensussan, N.; Heyman, M. Lactic acid bacteria secrete metabolites retaining antiinflammatory properties after intestinal transport. Gut, 2004, 53, 821-828.
46. Majamaa, H.; Isolauri, E. Probiotics: a novel approach in the management of food allergy. J. Allergy Clin. Immunol., 1997, 99, 179-185.
47. de Moreno de LeBlanc, A.; Matar, C.; Theriault, C.; Perdigon, G. Effects of milk fermented by Lactobacillus helveticus R389 on immune cells associated to mammary glands in normal and a breast cancer model. Immunobiology, 2005, 210, 349-358.
48. de Moreno de LeBlanc, A.; Matar, C.; LeBlanc, N.; Perdigon, G. Effects of milk fermented by Lactobacillus helveticus R389 on a murine breast cancer model. Breast Cancer Res., 2005, 7, R477-486.
49. Denardo, D. G.; Coussens, L. M. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res., 2007, 9, 212.
50. Condon, S. Responses of lactic acid bacteria to oxygen. FEMS Microbiol. Lett., 1987, 46, 269-280.
51. Ross, S. The involvement of oxygen radicals in microbicidal mechanism of leukocytes and macrophages. Klin Wochenschr. 1991, 69, 975-980.
52. Berlett, B. S.; Stadtman, E. R. Protein oxidation in aging, disease, and oxidative stress. J. Biol. Chem., 1997, 272, 20313-20316.
53. Farr, S. B.; Kogoma, T. Oxidative stress responses in Escherichia coli and Salmonella typhimurium. Microbiol. Rev., 1991, 55, 561-585.
54. Szatrowski, T. P.; Nathan, C. F. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res., 1991, 51, 794-798.
55. Keshavarzian, A.; Banan, A.; Farhadi, A.; Komanduri, S.; Mutlu, E.; Zhang, Y.; Fields, J. Z. Increases in free radicals and cytoskeletal protein oxidation and nitration in the colon of patients with inflammatory bowel disease. Gut, 2003, 52, 720-728.
56. Lih-Brody, L.; Powell, S. R.; Collier, K. P.; Reddy, G. M.; Cerchia, R.; Kahn, E.; Weissman, G. S.; Katz, S.; Floyd, R. A.; McKinley, M. J.; Fisher, S. E.; Mullin, G. E. Increased oxidative stress and decreased antioxidant defenses in mucosa of inflammatory bowel disease. Dig. Dis. Sci., 1996, 41, 2078-2086.
57. Sedghi, S.; Fields, J. Z.; Klamut, M.; Urban, G.; Durkin, M.; Winship, D.; Fretland, D.; Olyaee, M.; Keshavarzian, A. Increased production of luminol enhanced chemiluminescence by the inflamed colonic mucosa in patients with ulcerative colitis. Gut, 1993, 34, 1191-1197.
58. Simmonds, N. J.; Allen, R. E.; Stevens, T. R.; Van Someren, R. N.; Blake, D. R.; Rampton, D. S. Chemiluminescence assay of mucosal reactive oxygen metabolites in inflammatory bowel disease. Gastroenterology, 1992, 103, 186-196.
59. Kruidenier, L.; van Meeteren, M. E.; Kuiper, I.; Jaarsma, D.; Lamers, C. B.; Zijlstra, F. J.; Verspaget, H. W. Attenuated mild colonic inflammation and improved survival from severe DSS-colitis of transgenic Cu/Zn-SOD mice. Free Radic. Biol. Med., 2003, 34, 753-765.
60. Kruidenier, L.; Verspaget, H. W. Review article: oxidative stress as a pathogenic factor in inflammatory bowel disease--radicals or ridiculous? Aliment Pharmacol. Ther., 2002, 16, 1997-2015.
61. Rochat, T.; Miyoshi, A.; Gratadoux, J. J.; Duwat, P.; Sourice, S.; Azevedo, V.; Langella, P. High-level resistance to oxidative stress in Lactococcus lactis conferred by Bacillus subtilis catalase KatE. Microbiology, 2005, 151, 3011-3018.
62. Abriouel, H.; Herrmann, A.; Starke, J.; Yousif, N. M.; Wijaya, A.; Tauscher, B.; Holzapfel, W.; Franz, C. M. Cloning and heterologous expression of hematin-dependent catalase produced by Lactobacillus plantarum CNRZ 1228. Appl. Environ Microbiol., 2004, 70, 603-606.
63. Knauf, H. J.; Vogel, R. F.; Hammes, W. P. Cloning, sequence, and phenotypic expression of katA, which encodes the catalase of Lactobacillus sake LTH677. Appl. Environ Microbiol., 1992, 58, 832-839.
64. Noonpakdee, W.; Sitthimonchai, S.; Panyim, S.; Lertsiri, S. Expression of the catalase gene katA in starter culture Lactobacillus plantarum TISTR850 tolerates oxidative stress and reduces lipid oxidation in fermented meat product. Int. J. Food Microbiol., 2004, 95, 127-135.
65. Rochat, T.; Gratadoux, J. J.; Gruss, A.; Corthier, G.; Maguin, E.; Langella, P.; van de Guchte, M. Production of a heterologous nonheme catalase by Lactobacillus casei: an efficient tool for removal of H2O2 and protection of Lactobacillus bulgaricus from oxidative stress in milk. Appl. Environ Microbiol., 2006, 72, 5143-5149.
66. de Moreno de LeBlanc, A.; LeBlanc, J. G.; Perdigón, G.; Miyoshi, A.; Langella, P.; Azevedo, V.; Sesma, F. Oral administration of a catalase-producing Lactococcus lactis can prevent a chemically induced colon cancer in mice. J. Med. Microbiol., 2008, 58.
67. Rochat, T.; Bermudez-Humaran, L.; Gratadoux, J. J.; Fourage, C.; Hoebler, C.; Corthier, G.; Langella, P. Anti-inflammatory effects of Lactobacillus casei BL23 producing or not a manganese-dependant catalase on DSS-induced colitis in mice. Microb. Cell Fact., 2007, 6, 1-10.
68. Sanders, J. W.; Leenhouts, K. J.; Haandrikman, A. J.; Venema, G.; Kok, J. Stress response in Lactococcus lactis: cloning, expression analysis, and mutation of the lactococcal superoxide dismutase gene. J. Bacteriol., 1995, 177, 5254-5260.
69. Ogawa, Y.; Kanatsu, K.; Iino, T.; Kato, S.; Jeong, Y. I.; Shibata, N.; Takada, K.; Takeuchi, K. Protection against dextran sulfate sodium-induced colitis by microspheres of ellagic acid in rats. Life Sci., 2002, 71, 827-839.
70. Segui, J.; Gironella, M.; Sans, M.; Granell, S.; Gil, F.; Gimeno, M.; Coronel, P.; Pique, J. M.; Panes, J. Superoxide dismutase ameliorates TNBS-induced colitis by reducing oxidative stress, adhesion molecule expression, and leukocyte recruitment into the inflamed intestine. J. Leukoc Biol., 2004, 76, 537-544.
71. LeBlanc, J. G.; del Carmen, S.; Miyoshi, A.; Azevedo, V.; Sesma, F.; Langella, P.; Bermudez-Humaran, L. G.; Watterlot, L.; Perdigon, G.; de Moreno de LeBlanc, A. Use of superoxide dismutase and catalase producing lactic acid bacteria in TNBS induced Crohn's disease in mice. J. Biotechnol., 2011, 151, 287-293.
72. Han, W.; Mercenier, A.; Ait-Belgnaoui, A.; Pavan, S.; Lamine, F.; van, S., II; Kleerebezem, M.; Salvador-Cartier, C.; Hisbergues, M.; Bueno, L.; Theodorou, V.; Fioramonti, J. Improvement of an experimental colitis in rats by lactic acid bacteria producing superoxide dismutase. Inflamm Bowel Dis., 2006, 12, 1044-1052.
73. Carroll, I. M.; Andrus, J. M.; Bruno-Barcena, J. M.; Klaenhammer, T. R.; Hassan, H. M.; Threadgill, D. S. Anti-inflammatory properties of Lactobacillus gasseri expressing manganese superoxide dismutase using the interleukin 10-deficient mouse model of colitis. Am J Physiol Gastrointest Liver Physiol., 2007, 293, G729-738.
74. Watterlot, L.; Rochat, T.; Sokol, H.; Cherbuy, C.; Bouloufa, I.; Lefevre, F.; Gratadoux, J. J.; Honvo-Hueto, E.; Chilmonczyk, S.; Blugeon, S.; Corthier, G.; Langella, P.; Bermudez-Humaran, L. G. Intragastric administration of a superoxide dismutase-producing recombinant Lactobacillus casei BL23 strain attenuates DSS colitis in mice. Int. J. Food Microbiol., 2010, 144, 35-41.
75. Miyoshi, A.; Jamet, E.; Commissaire, J.; Renault, P.; Langella, P.; Azevedo, V. A xylose-inducible expression system for Lactococcus lactis. FEMS Microbiol Lett., 2004, 239, 205-212.
76. Marinho, F. A.; Pacifico, L. G.; Miyoshi, A.; Azevedo, V.; Le Loir, Y.; Guimaraes, V. D.; Langella, P.; Cassali, G. D.; Fonseca, C. T.; Oliveira, S. C. An intranasal administration of Lactococcus lactis strains expressing recombinant interleukin-10 modulates acute allergic airway inflammation in a murine model. Clin. Exp. Allergy, 2010, 40, 1541-1551.
77. del Carmen, S.; de Moreno de LeBlanc, A.; Perdigon, G.; Bastos Pereira, V.; Miyoshi, A.; Azevedo, V.; LeBlanc, J. G. Evaluation of the anti-inflammatory effect of milk fermented by a strain of IL-10 producing Lactococcus lactis using a murine model of Crohn's disease. J. Mol. Microbiol. Biotechnol., 2012, 21, 138-146.
78. Peran, L.; Camuesco, D.; Comalada, M.; Nieto, A.; Concha, A.; Diaz-Ropero, M. P.; Olivares, M.; Xaus, J.; Zarzuelo, A.; Galvez, J. Preventative effects of a probiotic, Lactobacillus salivarius ssp. salivarius, in the TNBS model of rat colitis. World J Gastroenterol. 2005, 11, 5185-5192.
79. Peran, L.; Sierra, S.; Comalada, M.; Lara-Villoslada, F.; Bailon, E.; Nieto, A.; Concha, A.; Olivares, M.; Zarzuelo, A.; Xaus, J.; Galvez, J. A comparative study of the preventative effects exerted by two probiotics, Lactobacillus reuteri and Lactobacillus fermentum, in the trinitrobenzenesulfonic acid model of rat colitis. Br. J. Nutr., 2007, 97, 96-103.
80. Matsumoto, S.; Hara, T.; Hori, T.; Mitsuyama, K.; Nagaoka, M.; Tomiyasu, N.; Suzuki, A.; Sata, M. Probiotic Lactobacillus-induced improvement in murine chronic inflammatory bowel disease is associated with the down-regulation of pro-inflammatory cytokines in lamina propria mononuclear cells. Clin. Exp. Immunol., 2005, 140, 417-426.
81. Osman, N.; Adawi, D.; Ahrne, S.; Jeppsson, B.; Molin, G. Modulation of the effect of dextran sulfate sodium-induced acute colitis by the administration of different probiotic strains of Lactobacillus and Bifidobacterium. Dig. Dis. Sci., 2004, 49, 320-327.
82. Herias, M. V.; Koninkx, J. F.; Vos, J. G.; Huis in't Veld, J. H.; van Dijk, J. E. Probiotic effects of Lactobacillus casei on DSS-induced ulcerative colitis in mice. Int. J. Food Microbiol., 2005, 103, 143-155.
83. Grabig, A.; Paclik, D.; Guzy, C.; Dankof, A.; Baumgart, D. C.; Erckenbrecht, J.; Raupach, B.; Sonnenborn, U.; Eckert, J.; Schumann, R. R.; Wiedenmann, B.; Dignass, A. U.; Sturm, A. Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2-and toll-like receptor 4-dependent pathways. Infect Immun., 2006, 74, 4075-4082.
84. Foligne, B.; Zoumpopoulou, G.; Dewulf, J.; Ben Younes, A.; Chareyre, F.; Sirard, J. C.; Pot, B.; Grangette, C. A key role of dendritic cells in probiotic functionality. PLoS One, 2007, 2, e313.
85. Lee, H. S.; Han, S. Y.; Bae, E. A.; Huh, C. S.; Ahn, Y. T.; Lee, J. H.; Kim, D. H. Lactic acid bacteria inhibit proinflammatory cytokine expression and bacterial glycosaminoglycan degradation activity in dextran sulfate sodium-induced colitic mice. Int. Immunopharmacol., 2008, 8, 574-580.
86. Nishitani, Y.; Tanoue, T.; Yamada, K.; Ishida, T.; Yoshida, M.; Azuma, T.; Mizuno, M. Lactococcus lactis subsp. cremoris FC alleviates symptoms of colitis induced by dextran sulfate sodium in mice. Int. Immunopharmacol., 2009, 9, 1444-1451.
87. Lee, B.; Lee, J. H.; Lee, H. S.; Bae, E. A.; Huh, C. S.; Ahn, Y. T.; Kim, D. H. Glycosaminoglycan degradation-inhibitory lactic acid bacteria ameliorate 2,4,6-trinitrobenzenesulfonic acid-induced colitis in mice. J. Microbiol. Biotechnol., 2009, 19, 616-621.
88. Hormannsperger, G.; Clavel, T.; Hoffmann, M.; Reiff, C.; Kelly, D.; Loh, G.; Blaut, M.; Holzlwimmer, G.; Haller, D. Posttranslational inhibition of proinflammatory chemokine secretion in intestinal epithelial cells: implications for specific IBD indications. J Clin. Gastroenterol., 2010, 44 Suppl 1, S10-15.
89. Philippe, D.; Heupel, E.; Blum-Sperisen, S.; Riedel, C. U. Treatment with Bifidobacterium bifidum 17 partially protects mice from Th1-driven inflammation in a chemically induced model of colitis. Int. J. Food Microbiol., 2011, 149, 45-49.
90. Duary, R. K.; Bhausaheb, M. A.; Batish, V. K.; Grover, S. Antiinflammatory and immunomodulatory efficacy of indigenous probiotic Lactobacillus plantarum Lp91 in colitis mouse model. Mol. Biol. Rep.
91. de Moreno de LeBlanc, A.; Chaves, S.; Perdigon, G. Effect of yoghhurt on the cytokine profile using a murine model of intestinal inflammation. Eur. J. Inflam., 2009, 7 97-109.
92. Chaves, S.; Perdigon, G.; de Moreno de LeBlanc, A. Yoghurt consumption regulates the immune cells implicated in acute intestinal inflammation and prevents the recurrence of the inflammatory process in a mouse model. J. Food Prot., 2011, 74, 801-811.
93. Grangette, C.; Nutten, S.; Palumbo, E.; Morath, S.; Hermann, C.; Dewulf, J.; Pot, B.; Hartung, T.; Hols, P.; Mercenier, A. Enhanced antiinflammatory capacity of a Lactobacillus plantarum mutant synthesizing modified teichoic acids. Proc. Natl. Acad. Sci. U.S.A., 2005, 102, 10321-10326.